Colorectal cancer (RCC) is an uncontrolled growth of the cells of the colon and / or rectum. Most colorectal cancers begin as a growth in the inner lining of the colon or rectum, which is called a polyp. Some types of polyps can become cancer over time, but not all polyps become cancer. Colorectal tumors can originate in each of the three layers of the colon: mucous, muscular and serous.
This type of cancer is the second most common cancer in women and the third most common in men, and also the easiest to diagnose. In addition, if detected early, cure rates are high. Incidence is correlated with advancing age and, in developed countries, the median age at diagnosis is approximately 70 years
Colon cancer can grow in three ways:
Local growth: In this case the tumor deeply invades all layers of the wall of the digestive tract.
Lymphatic dissemination: When the tumor can reach other organs using the network of lymphatic vessels that allow access to multiple ganglion regions.
Hematogenous dissemination: the tumor spreads through the bloodstream to liver, lung, bone and brain cells, mainly.
Management of CRC has evolved significantly in the past 20 years, and survival rates have improved during this time. Some of the treatments for colorectal cancer are:
Surgery: Through an operation in the operating room, the part affected by the cancer is removed. Surgery is used in all stages of the disease.
Radiation therapy: It consists of applying high-energy radiation on the affected area in order to destroy the cancer cells. It only affects the area under treatment and can be applied before surgery (to reduce the tumor and be able to remove it more easily) or after surgery (to finish destroying the cancer cells that may have remained).
Chemotherapy: It is the treatment by which drugs are administered with the aim of destroying cancer cells.
Immunotherapy: Immunotherapy, which involves stimulating or restoring the body’s own immune defenses, however, in colon cancer it is still very ineffective.
Although these treatments have contributed to improve clinical outcomes, a key development has been the introduction of new biological therapies aimed at epidermal growth factor signaling or angiogenesis. Among these therapies, is Bevacizumab, a monoclonal antibody directed against vascular endothelial growth factor. Some of these treatments (Targeted therapy, immunotherapy) are used in Althian for the treatment of different types of cancer (mainly Lung Cancer, and renal cancer) in which a good result has been observed. Feel free to contact us for more information.